Brief: EFFECTOR Therapeutics Announces Positive Top-Line Results From Phase 1b Clinical Trial Of Zotatifin
Feb 21 (Reuters) - eFFECTOR Therapeutics Inc EFTR.O :
* EFFECTOR THERAPEUTICS ANNOUNCES POSITIVE TOP-LINE RESULTS
FROM
PHASE 1B CLINICAL TRIAL OF ZOTATIFIN FOR THE TREATMENT OF COVID
* EFFECTOR THERAPEUTICS - ZOTATIFIN FOR TREATMENT OF COVID
SHOWING
FAVORABLE SAFETY RESULTS, POSITIVE TRENDS IN SEVERAL MEASURES OF
ANTIVIRAL ACTIVITY
Source text for Eikon: ID:nGNX50P5ZN
Further company coverage: EFTR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Effector Therapeutics
See all newsBrief: Effector Therapeutics Expects To Incur One-Time Charges And Cash Expenditures
Brief: Effector Therapeutics Announces It Will Wind Down Operations
Brief: Effector Therapeutics To Collaborate With The Dana-Farber Cancer Institute
eFFECTOR Therapeutics Inc reports results for the quarter ended in January - Earnings Summary
Brief: eFFECTOR Therapeutics Enters Into An At The Market Offering Agreement With H.C. Wainwright